NCT00573573

Brief Summary

A study to determine the possibility of using far infrared radiation to treat Hyperparathyroidism.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2

participants targeted

Target at below P25 for phase_1

Timeline
Completed

Started Jan 2007

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

December 12, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 14, 2007

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2009

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2009

Completed
Last Updated

March 24, 2009

Status Verified

March 1, 2009

Enrollment Period

2.2 years

First QC Date

December 12, 2007

Last Update Submit

March 23, 2009

Conditions

Hyperparathyroidism

Keywords

PRIMARY HYPERPARATHYROIDISMPARATHYROID NEOPLASMSSECONDARY HYPERPARATHYROIDISMHYPOCALCEMIA

Outcome Measures

Primary Outcomes (1)

  • The primary end point is to determine the therapeutic effects of far infrared radiation on Hyperparathyroidism.

    2 years

Secondary Outcomes (1)

  • Effect of far infrared radiation treatment on other immune deficiency diseases like thyroidism and diabetes

    2 years

Study Arms (1)

1

OTHER
Radiation: Far Infrared Radiation

Interventions

Far Infrared RadiationRADIATION

Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.

1

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Persons with parathyroid disease

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Centre for Incurable Diseases

Toronto, Ontario, M4V 1L5, Canada

Location

MeSH Terms

Conditions

HyperparathyroidismHyperparathyroidism, PrimaryParathyroid NeoplasmsHyperparathyroidism, SecondaryHypocalcemia

Condition Hierarchy (Ancestors)

Parathyroid DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsCalcium Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesWater-Electrolyte Imbalance

Study Officials

  • Ken Nedd, M.D.

    GAAD Medical Research Institute Inc.

    STUDY DIRECTOR

  • Kwasi Donyina, Ph.D.

    GAAD Medical Research Institute Inc.

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 12, 2007

First Posted

December 14, 2007

Study Start

January 1, 2007

Primary Completion

March 1, 2009

Study Completion

July 1, 2009

Last Updated

March 24, 2009

Record last verified: 2009-03

Locations

CA(1)